V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 160013184 | 160006392 | 1.63 | 75.7 | Curative (C) | 2017-10-17 | 2017-11-10 | Cisplatin + Pemetrexed | N | N | CISPLATIN + PEMETREXED | 101200562 |
| 160013185 | 160006393 | 1.71 | 48.2 | Palliative (P) | 2019-11-21 | 2019-11-23 | STS Rhabdomyosarco RMS 2005 IVADoVV | 02 | N | DOXORUBICIN + IFOSFAMIDE | 100965152 |
| 160013186 | 160006394 | 1.78 | 80.9 | Palliative (P) | 2017-05-26 | 2017-05-27 | Cisplatin + Pemetrexed | 02 | null | CISPLATIN + PEMETREXED | 101510352 |
| 160013187 | 160006395 | 1.74 | 78.6 | Palliative (P) | 2015-06-11 | 2015-06-17 | Cisplatin + Pemetrexed | N | N | CISPLATIN + PEMETREXED | 100311391 |
| 160013189 | 160006396 | 1.73 | 59.8 | Palliative (P) | 2014-03-16 | 2014-04-28 | Liposomal Doxorubicin (20mg/m2) | 02 | N | ENZALUTAMIDE | 101719448 |
| 160013190 | 160006397 | 1.72 | 63.6 | Palliative (P) | 2017-10-04 | 2017-10-04 | Doxorubicin 75mg/m2 | N | null | DOXORUBICIN | 100645166 |
| 160013191 | 160006398 | null | null | Palliative (P) | 2018-10-29 | 2018-11-05 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100387782 |
| 160013192 | 160006399 | 1.8 | 71.3 | Palliative (P) | 2018-06-03 | 2018-06-10 | Avelumab | 02 | N | CYCLOPHOSPHAMIDE | 101119121 |
| 160013193 | 160006400 | null | null | null | 2018-10-08 | 2018-10-22 | Abiraterone | 01 | N | TRIAL UNSPECIFIED | 101549326 |
| 160013194 | 160006401 | 1.64 | 146.3 | Curative (C) | 2016-11-08 | 2016-12-02 | Bendamustine+Rituximab (1st Course) | 02 | N | LIPOSOMAL DOXORUBICIN | 100674482 |
| 160013195 | 160006402 | 1.68 | 67.6 | Palliative (P) | 2016-10-09 | 2016-10-12 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101200734 |
| 160013198 | 160006403 | 1.72 | 61.9 | Palliative (P) | 2019-11-23 | 2019-11-30 | Cisplatin + Doxorubicin | 02 | null | TRIAL UNSPECIFIED | 100492605 |
| 160013201 | 160006404 | 1.7 | 88 | Neo-adjuvant (N) | 2017-10-05 | 2017-10-05 | Cisplatin + Pemetrexed | N | N | CISPLATIN + PEMETREXED | 100011217 |
| 160013202 | 160006405 | 1.6 | 61 | 03 | 2018-04-06 | 2018-04-14 | Doxorubicin + Olaratumab | 01 | N | TRIAL | 101077199 |
| 160013205 | 160006406 | 1.75 | 94 | Palliative (P) | 2017-07-13 | 2017-07-26 | Cisplatin + Pemetrexed | N | N | CISPLATIN + PEMETREXED | 100730350 |
| 160013206 | 160006407 | 1.75 | 80 | Palliative (P) | 2019-01-01 | 2019-01-01 | Cisplatin + Pemetrexed | N | N | CISPLATIN + PEMETREXED | 100535539 |
| 160013207 | 160006408 | 1.2 | 62 | Curative (C) | 2018-01-21 | 2018-05-07 | Bevacizumab 7.5mg/kg | null | N | CARBOPLATIN + ETOPOSIDE | 100082205 |
| 160013209 | 160006409 | 1.74 | 84 | Palliative (P) | null | 2018-12-23 | Cisplatin + Pemetrexed | 02 | Y | CISPLATIN + PEMETREXED | 101654568 |
| 160013210 | 160006410 | 1.78 | 98.6 | Curative (C) | 2018-03-19 | 2018-04-03 | Cisplatin + Pemetrexed | N | N | CISPLATIN + PEMETREXED | 100621302 |
| 160013213 | 160006411 | 1.84 | 51 | null | 2018-02-23 | 2018-03-18 | Cisplatin + Pemetrexed | 02 | null | CISPLATIN + PEMETREXED | 100595456 |
| 160013214 | 160006412 | 1.7 | 66.4 | Neo-adjuvant (N) | 2019-07-11 | 2019-07-11 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100457641 |
| 160013215 | 160006413 | 1.74 | 77.4 | Neo-adjuvant (N) | 2018-08-21 | 2018-09-04 | PACLITAXEL | 02 | N | DACTINOMYCIN + IFOSFAMIDE + VINCRISTINE | 100845242 |
| 160013216 | 160006414 | null | null | Palliative (P) | null | 2018-08-12 | Cisplatin + Pemetrexed | 02 | null | CISPLATIN + PEMETREXED | 100940128 |
| 160013217 | 160006415 | 1.86 | 77.3 | Palliative (P) | 2018-03-13 | 2018-03-19 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100744196 |
| 160013220 | 160006416 | 1.81 | null | null | 2017-03-30 | 2017-04-20 | Cisplatin + Pemetrexed | N | null | CISPLATIN + PEMETREXED | 101281478 |
| 160013223 | 160006417 | 1.72 | 54.6 | Palliative (P) | null | 2018-02-02 | Liposomal Doxorubicin (Caelyx) | 02 | null | ECX | 101563907 |
| 160013224 | 160006418 | 1.77 | 86.2 | Neo-adjuvant (N) | 2017-04-24 | 2017-05-11 | Trial Unspecified | 02 | N | IFOSFAMIDE | 100688571 |
| 160013232 | 160006420 | null | null | Curative (C) | 2017-08-15 | 2017-09-03 | Cisplatin + Docetaxel +Fluorouracil | 02 | null | ETOPOSIDE + IFOSFAMIDE | 101299036 |
| 160013233 | 160006421 | 1.61 | 77 | Palliative (P) | 2018-02-22 | 2018-10-27 | Trial Unspecified | 01 | N | STS RHABDOMYOSARCO RMS 2005 IVADOVV | 101299490 |
| 160013234 | 160006422 | 1.77 | 54 | Palliative (P) | 2018-04-25 | 2018-04-25 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101141365 |
| 160013235 | 160006423 | 1.61 | 67.8 | Palliative (P) | 2017-09-11 | 2017-09-11 | PACLITAXEL | 02 | N | STS RHABDOMYOSARCOMA RMS 2005 IVAVV | 101000259 |
| 160013236 | 160006424 | 1.64 | 97.85 | Palliative (P) | 2017-04-22 | 2017-05-08 | STS Rhabdomyosarcoma RMS 2005 IVAVV | null | N | EW EUROEWING 2012 ARM B VDC | 101410012 |
| 160013238 | 160006425 | null | null | Neo-adjuvant (N) | null | 2019-07-02 | Pemetrexed | 02 | null | MELPHALAN | 101706243 |
| 160013241 | 160006426 | 1.66 | 97 | Adjuvant (A) | 2018-03-26 | 2018-03-26 | VIDE | 02 | N | DOXORUBICIN + OLARATUMAB | 101264677 |
| 160013242 | 160006427 | 1.65 | 87.4 | Palliative (P) | 2019-10-27 | 2019-10-27 | CYCLOPHOSPHAMIDE + DOXORUBICIN + ETOPOSIDE + VINCRISTINE | 02 | N | DOXORUBICIN + IFOSFAMIDE | 101363342 |
| 160013243 | 160006428 | 1.7 | 80 | 03 | 2017-07-18 | 2017-07-18 | Paclitaxel 80mg/m2 day 1 8 15 | 02 | N | ATOMIC-MESO TRIAL | 101768854 |
| 160013244 | 160006429 | 1.74 | 73.4 | Curative (C) | null | 2018-10-22 | Cisplatin + Pemetrexed | 2 | N | CISPLATIN + PEMETREXED | 101799097 |
| 160013245 | 160006430 | 1.69 | 76 | Palliative (P) | 2019-06-05 | 2019-06-06 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100934321 |
| 160013247 | 160006431 | 1.63 | 99 | null | 2018-02-18 | 2018-03-09 | Doxorubicin 75mg/m2 | 2 | N | STS RHABDO RMS 2005 VIN CYCLO | 100827806 |
| 160013248 | 160006432 | 1.72 | 81.9 | Curative (C) | 2018-07-26 | 2018-07-26 | Cisplatin + Pemetrexed | null | N | CISPLATIN + PEMETREXED | 100579368 |
| 160013249 | 160006433 | 1.79 | 86.6 | Palliative (P) | 2019-11-15 | 2019-11-30 | NB Low/Interm risk guidelines Carbo/Etop | 02 | N | CARBOPLATIN + ETOPOSIDE | 101588170 |
| 160013250 | 160006434 | 1.7 | 77.1 | Palliative (P) | 2020-06-03 | 2020-07-14 | Cisplatin + Pemetrexed | 2 | N | CISPLATIN + PEMETREXED | 100251324 |
| 160013251 | 160006435 | 1.76 | 72 | Neo-adjuvant (N) | 2018-05-11 | 2018-06-15 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100596149 |
| 160013252 | 160006436 | 0.5 | 101.9 | Curative (C) | 2016-02-04 | 2017-02-22 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101772463 |
| 160013254 | 160006437 | 1.6 | 54 | Palliative (P) | 2020-04-29 | 2020-05-09 | Trial Unspecified | 02 | N | DOXORUBICIN | 101065153 |
| 160013255 | 160006438 | 1.73 | 107.1 | Palliative (P) | 2017-12-18 | 2017-12-31 | Cisplatin + Pemetrexed | N | N | CISPLATIN + PEMETREXED | 101240133 |
| 160013256 | 160006439 | 1.73 | 77.5 | Neo-adjuvant (N) | 2018-07-25 | 2018-08-11 | ICON8B TRIAL | N | N | ETOP 13-18 BEAT-MESO TRIAL | 101670964 |
| 160013259 | 160006440 | 1.74 | 75 | Neo-adjuvant (N) | 2018-12-16 | 2018-12-17 | Liposomal Doxorubicin (Caelyx) | N | null | CISPLATIN + GEMCITABINE | 100750835 |
| 160013261 | 160006441 | 1.69 | 94.7 | Palliative (P) | 2019-07-09 | 2019-07-10 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100678453 |
| 160013263 | 160006442 | 1.59 | 79.5 | Palliative (P) | 2018-04-11 | 2018-04-17 | Liposomal Doxorubicin 40mg/m2 | 02 | N | TRIAL UNSPECIFIED | 100673023 |